'The European Medicines Agency Just Disclosed That Rocket Pharmaceuticals Has Withdrawn Its Application For Marketing Authorization Of Fanskya; The EMA Concluded That The Benefit Of Mozafancogene Autotemcel Did Not Outweigh Its Risks' - EMA
Benzinga Newsdesk 1 year ago
BiotechNewsFDAGeneral
https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_en.pdf